Physician profile
Ivan Srdanovic
NPI 1184262735
$2,606.61
in general payments reported to CMS, 2019-2025
19 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,687 · 2024: $397 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,558 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.77 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $652.07 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $405.50 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $365.97 | 2024-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $303.13 | 2023-2025 | Rexulti, Abilify Mycite |
| Alkermes, INC. | $156.29 | 2023 | Aristada, Lybalvi |
| Lundbeck LLC | $142.75 | 2023 | Rexulti, Abilify Maintena |
| Janssen Scientific Affairs, LLC | $120.06 | 2024 | Spravato |
| Noven Therapeutics, LLC | $102.40 | 2023-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $70.97 | 2023-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $54.42 | 2023-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $53.99 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $41.38 | 2023 | Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $29.37 | 2025 | |
| Collegium Pharmaceutical, INC. | $22.56 | 2025 | Jornay Pm |
| Biogen, INC. | $19.05 | 2025 | Zurzuvae |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $17.99 | 2023 | Perseris |
| Avion Pharmaceuticals | $17.85 | 2023 | Methylphenidate Hydrochloride |
| Idorsia Pharmaceuticals US INC | $16.19 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $14.67 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Srdanovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.